Library / regulatory-reference
Iceland: Icelandic Medicines Agency (IMA)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The Icelandic Medicines Agency, known as the IMA, is Iceland's national regulatory authority for medicines and medical devices.
Iceland's small market participates in the European single market through its economic-area membership, so the agency works within the European regulatory network while serving one of Europe's smallest populations.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, and establishments are licensed and inspected by the agency.
Post-market work includes safety monitoring within the European alert network, with reliance on shared European assessments essential for a small agency.
Regional and international role
The agency is a member of the European regulatory network through Iceland's economic-area membership and cooperates closely with Nordic neighbors.
Its experience shows how the smallest authorities participate fully in a shared regulatory system: European assessments carry most of the scientific load.
Using this profile
The agency publishes regulations and announcements in Icelandic and English through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: Iceland illustrates the micro-state inside a big network: national licensing on top of shared European scientific work.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.